Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596323 · ClinicalTrials.gov registry record
Implantable Antenna Sensors for Continuous Glucose Monitoring
A clinical trial of Type 1 Diabetes Mellitus, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00596323 is a study of Type 1 Diabetes Mellitus that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 10 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00596323, a study of Type 1 Diabetes Mellitus, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers' long-term goal is to develop a small implantable device that can continually monitor glucose levels. This will be an antenna. Changes in the glucose levels in will affect the antenna signals and those can be used to predict the patient's glucose levels.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama Children's Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596323
The ClinicalTrials.gov registry entry for NCT00596323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (93% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT00596323 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00596323 about?
NCT00596323 is a clinical study titled "Implantable Antenna Sensors for Continuous Glucose Monitoring". The researchers' long-term goal is to develop a small implantable device that can continually monitor glucose levels. This will be an antenna. Changes in the glucose levels in will affect the antenna signals and those can be used to predict the patient's glucose levels.
What is the current status of trial NCT00596323?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2007-06. Estimated completion is 2008-06.
What conditions does trial NCT00596323 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
Who is sponsoring clinical trial NCT00596323?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00596323 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.